Cancer Drug Dosing Under Fire: Could Lower Doses Cut Costs and Side Effects?

A growing number of patients and researchers argue that many FDA-approved cancer drug dosages are higher than necessary. They cite evidence that reducing the amount and frequency of these treatments could save billions of dollars and lessen severe side effects. The challenge targets widely used immunotherapies like Keytruda and Opdivo.